Novartis Gets FDA Approval for Lutathera in Pediatric Treatment
By Dean Seal
Novartis said federal regulators have approved its Lutathera therapy as a treatment for pediatric patients with certain gastroenteropancreatic neuroendocrine tumors.
The Swiss pharmaceutical company said Tuesday that the Food and Drug Administration has approved the therapy for the treatment of patients aged 12 and older with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors, including foregut, midgut, and hindgut neuroendocrine tumors.
The approval makes Lutathera the first therapy that has been specifically reviewed and approved for use in pediatric patients with gastroenteropancreatic neuroendocrine tumors, Novartis said.
The approval was based on a trial that reported a safety profile for Lutathera that was consistent with an adult population in a previous study that ultimately got the therapy approved for adult patients.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
April 23, 2024 14:18 ET (18:18 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
5 Undervalued Stocks to Buy as Their Stories Play Out
-
Markets Brief: Return of the Meme Stocks
-
What’s Happening In the Markets This Week
-
What Does Nvidia’s Stock Split Mean for Investors?
-
It’s Been a Terrible Time for Bonds. Here’s Why You Should Own Them
-
Which AI Stocks Are Turning Hype Into Revenue?
-
Best- and Worst-Performing Stocks of May 2024
-
3 Stocks to Buy and 3 Stocks to Sell in June
-
Apple: Generative AI Announcements Fit With Our Expectations
-
2 Undervalued Stocks That Just Raised Dividends
-
2 Popular Stocks That Top Managers Are Selling
-
The Best REITs to Buy
-
Nio Earnings: Revenue and Loss Largely In Line, but Vehicle Margin Missed Amid Price Competition
-
The Best Biotech Stocks to Buy
-
After Earnings, Is Marvell Stock a Buy, a Sell, or Fairly Valued?
-
Nvidia Raised Its Dividend — but There’s a Catch